AZD1208 AZD-1208 CAS: 1204144-28-4

CAS NO: 1204144-28-4
AZD1208 AZD-1208
Chemical Name: AZD-1208
Molecular Formula: C21H21N3O2S
Formula Weight: 379.48
CAS No.: 1204144-28-4
Description Review
Description

AZD1208, also known as AZD-1208 CAS: 1204144-28-4, is a small molecule inhibitor that has shown promise in the treatment of various cancers. This product is primarily known for its ability to inhibit protein kinase B (PKB/Akt), which plays a key role in tumor development and progression. In this article, we will explore the chemical properties of AZD1208, its potential health benefits, safety considerations, and dosing information.

Chemical name:

The chemical name for AZD1208 is N-(2,4-dimethylpyridin-3-yl)-4-((4-(morpholinomethyl)phenyl)amino)-1H-pyrazole-3-carboxamide.

Molecular formula:

The molecular formula of AZD1208 is C21H25N5O2.

Formula weight:

The molecular weight of AZD1208 is 383.46 g/mol.

CAS No:

The CAS number for AZD1208 is 1204144-28-4.

Top ten keywords from Google and Synonyms Synonym:

  1. Akt inhibitors
  2. Cancer treatment
  3. Tumor growth
  4. Cell signaling
  5. Chemotherapy
  6. Prostate cancer
  7. Breast cancer
  8. Targeted therapy
  9. Drug resistance
  10. Apoptosis

Health benefits of this product:

AZD1208 has been found to have a variety of potential health benefits. One of the most studied applications of this compound is in the treatment of cancer. Specifically, AZD1208 may be effective in treating prostate cancer, breast cancer, and other tumors. Studies have shown that AZD1208 can inhibit PKB/Akt enzymes, leading to apoptosis, decreased tumor growth, and improved survival rates.

In addition to cancer treatment, AZD1208 may also have potential in the treatment of other conditions related to cell signaling and protein synthesis. These conditions include neurodegenerative disorders such as Alzheimer's disease.

Potential effects:

AZD1208 works by inhibiting the activity of PKB/Akt enzymes. PKB/Akt enzymes play a critical role in regulating many cellular processes, including protein synthesis, cell survival, and apoptosis. By inhibiting these enzymes, AZD1208 may be able to influence these processes and potentially affect the development and progression of various diseases.

Product mechanism:

The precise mechanism of action of AZD1208 is not well understood, but it is believed to work by binding to and inhibiting the activity of PKB/Akt enzymes.

Safety:

AZD1208 is generally considered to be safe when used as directed. However, as with any medication or supplement, there is some risk of side effects. It is important to consult with a healthcare provider before using AZD1208, especially if you have any underlying medical conditions or are taking other medications.

Side effects:

Some potential side effects of AZD1208 include nausea, vomiting, fatigue, and diarrhea. More serious side effects may include liver toxicity and blood disorders. If you experience any of these symptoms or other severe side effects, you should seek medical attention immediately.

Dosing information:

The optimal dosage of AZD1208 will depend on the specific application and the individual's needs. It is important to follow the dosing instructions provided by a healthcare provider or on the product label. In general, doses of AZD1208 in the range of 30-60 mg/kg per day have been used in animal studies.

Conclusion:

AZD1208 is a promising compound with potential health benefits in the treatment of cancer and other diseases related to cell signaling and protein synthesis. Its mechanism of action through the inhibition of PKB/Akt enzymes is a promising avenue for new drug therapies. While generally safe, it is important to consult with a healthcare provider before using AZD1208 and to follow dosing instructions carefully. Further research is needed to fully understand the potential benefits and risks of this compound

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code
Message Us